Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity

被引：41

作者：

Fanning, S. W. ^{[1
]}

Hodges-Gallagher, L. ^{[2
]}

Myles, D. C. ^{[2
]}

Sun, R. ^{[2
]}

Fowler, C. E. ^{[1
]}

Plant, I. N. ^{[3
]}

Green, B. D. ^{[1
]}

Harmon, C. L. ^{[2
]}

Greene, G. L. ^{[1
]}

Kushner, P. J. ^{[2
]}

机构：

[1] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA

[2] Olema Pharmaceut, San Francisco, CA 94107 USA

[3] Harvard Med Sch, Dept Syst Biol, Boston, MA 02115 USA

来源：

NATURE COMMUNICATIONS | 2018年 / 9卷

关键词：

BREAST-TUMORS; ER-ALPHA; PROMOTER-CONTEXT; FULVESTRANT; BINDING; MECHANISMS; RESISTANCE; ANTAGONISM; GROWTH; BONE;

D O I：

10.1038/s41467-018-04413-3

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer. Pure ER antagonists, which completely lack tissue-specific agonist activity, hold promise for preventing and treating endocrine resistance, however an absence of structural information hinders the development of novel candidates. Here we synthesize a small panel of benzopyrans with variable side chains to identify pure antiestrogens in a uterotrophic assay. We identify OP-1074 as a pure antiestrogen and a selective ER degrader (PA-SERD) that is efficacious in shrinking tumors in a tamoxifen-resistant xenograft model. Biochemical and crystal structure analyses reveal a structure activity relationship implicating the importance of a stereospecific methyl on the pyrrolidine side chain of OP-1074, particularly on helix 12.

引用

页数：12

共 50 条

[11] RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models [J].

Garner, Fiona ;

Shomali, Maysoun ;

Paquin, Dotty ;

Lyttle, C. Richard ;

Hattersley, Gary .

ANTI-CANCER DRUGS, 2015, 26 (09) :948-956

[12] Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator.: Study of nitrogen substitution [J].

Gauthier, S ;

Cloutier, J ;

Dory, YL ;

Favre, A ;

Mailhot, J ;

Ouellet, C ;

Schwerdtfeger, A ;

Mérand, Y ;

Martel, C ;

Simard, J ;

Labrie, F .

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2005, 20 (02) :165-177

[13] A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation [J].

Geiser, AG ;

Hummel, CW ;

Draper, MW ;

Henck, JW ;

Cohen, IR ;

Rudmann, DG ;

Donnelly, KB ;

Adrian, MD ;

Shepherd, TA ;

Wallace, OB ;

McCann, DJ ;

Oldham, SW ;

Bryant, HU ;

Sato, M ;

Dodge, JA .

ENDOCRINOLOGY, 2005, 146 (10) :4524-4535

[14] First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer [J].

Goetz, Matthew P. ;

Suman, Vera J. ;

Reid, Joel M. ;

Northfelt, Don W. ;

Mahr, Michael A. ;

Ralya, Andrew T. ;

Kuffel, Mary ;

Buhrow, Sarah A. ;

Safgren, Stephanie L. ;

McGovern, Renee M. ;

Black, John ;

Dockter, Travis ;

Haddad, Tufia ;

Erlichman, Charles ;

Adjei, Alex A. ;

Visscher, Dan ;

Chalmers, Zachary R. ;

Frampton, Garrett ;

Kipp, Benjamin R. ;

Liu, Minetta C. ;

Hawse, John R. ;

Doroshow, James H. ;

Collins, Jerry M. ;

Streicher, Howard ;

Ames, Matthew M. ;

Ingle, James N. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (30) :3391-+

[15]

HOLINKA CF, 1986, CANCER RES, V46, P2771

[16] Pure oestrogen antagonists for the treatment of advanced breast cancer [J].

Howell, Anthony .

[17] Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer [J].

Jeselsohn, Rinath ;

Yelensky, Roman ;

Buchwalter, Gilles ;

Frampton, Garrett ;

Meric-Bernstam, Funda ;

Gonzalez-Angulo, Ana Maria ;

Ferrer-Lozano, Jaime ;

Perez-Fidalgo, Jose A. ;

Cristofanilli, Massimo ;

Gomez, Henry ;

Arteaga, Carlos L. ;

Giltnane, Jennifer ;

Balko, Justin M. ;

Cronin, Maureen T. ;

Jarosz, Mirna ;

Sun, James ;

Hawryluk, Matthew ;

Lipson, Doron ;

Otto, Geoff ;

Ross, Jeffrey S. ;

Dvir, Addie ;

Soussan-Gutman, Lior ;

Wolf, Ido ;

Rubinek, Tamar ;

Gilmore, Lauren ;

Schnitt, Stuart ;

Come, Steven E. ;

Pusztai, Lajos ;

Stephens, Philip ;

Brown, Myles ;

Miller, Vincent A. .

CLINICAL CANCER RESEARCH, 2014, 20 (07) :1757-1767

[18]

Johnston SRD, 1999, CLIN CANCER RES, V5, P251

[19] The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER plus breast cancer [J].

Joseph, James D. ;

Darimont, Beatrice ;

Zhou, Wei ;

Arrazate, Alfonso ;

Young, Amy ;

Ingalla, Ellen ;

Walter, Kimberly ;

Blake, Robert A. ;

Nonomiya, Jim ;

Guan, Zhengyu ;

Kategaya, Lorna ;

Govek, Steven P. ;

Lai, Andiliy G. ;

Kahraman, Mehmet ;

Brigham, Dan ;

Sensintaffar, John ;

Lui, Nhin ;

Sheo, Gang ;

Qian, Jing ;

Grillot, Kate ;

Moon, Michael ;

Prudente, Rene ;

Bischoff, Eric ;

Lee, Kyoung-Jin ;

Bonnefous, Celine ;

Douglas, Karensa L. ;

Julien, Jackaline D. ;

Nagasawa, Johnny Y. ;

Aparicio, Anna ;

Kaufman, Josh ;

Haley, Benjamin ;

Giltnane, Jennifer M. ;

Wertz, Ingrid E. ;

Lackner, Mark R. ;

Nannini, Michelle A. ;

Sampath, Deepak ;

Schwarz, Luis ;

Manning, Henry Charles ;

Tantawy, Mohammed Noor ;

Arteaga, Carlos L. ;

Heyman, Richard A. ;

Rix, Peter J. ;

Friedman, Lori ;

Smith, Nicholas D. ;

Metcalfe, Ciara ;

Hager, Jeffrey H. .

ELIFE, 2016, 5

[20] ACTIVATION OF THE ESTROGEN-RECEPTOR THROUGH PHOSPHORYLATION BY MITOGEN-ACTIVATED PROTEIN-KINASE [J].

KATO, S ;

ENDOH, H ;

MASUHIRO, Y ;

KITAMOTO, T ;

UCHIYAMA, S ;

SASAKI, H ;

MASUSHIGE, S ;

GOTOH, Y ;

NISHIDA, E ;

KAWASHIMA, H ;

METZGER, D ;

CHAMBON, P .

SCIENCE, 1995, 270 (5241) :1491-1494

← 1 2 3 4 5 →